Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV

被引:165
作者
Schechter, M
do Lago, RF
Mendelsohn, AB
Moreira, RI
Moulton, LH
Harrison, LH
机构
[1] Univ Fed Rio de Janeiro, Hosp Univ Clementino Fraga Filho, AIDS Res Lab, Infect Dis Serv, BR-21941590 Rio De Janeiro, Brazil
[2] Univ Fed Rio de Janeiro, Dept Prevent Med, BR-21941590 Rio De Janeiro, Brazil
[3] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA
[4] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA
[5] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA
[6] Univ Pittsburgh, Grad Sch Publ Hlth, Infect Dis Epidemiol Res Unit, Pittsburgh, PA USA
[7] Univ Pittsburgh, Sch Med, Infect Dis Epidemiol Res Unit, Pittsburgh, PA USA
关键词
postexposure chemoprophylaxis; postexposure prophylaxis; HIV; HIV incidence; lamivudine; zidovudine;
D O I
10.1097/00126334-200404150-00010
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Little is known about the behavioral impact, acceptability, and incidence of HIV infection in persons with easy access to post-sexual exposure prophylaxis (PEP) to prevent HIV. Methods: Participants were recruited from a well-characterized, high-risk HIV seronegative homosexual male cohort in Rio de Janeiro, Brazil, given a 4-day supply of zidovudine and lamivudine, and instructed to begin PEP immediately after an eligible exposure. For eligible exposures, an additional 24-day supply was provided. Reported behavior, PEP utilization, adverse events, and incident HIV infection were the main study outcomes. The observed and expected incidences of HIV infection were compared. Results: Two hundred subjects were enrolled and followed for a median of 24.2 months. The median age was 28 years. PEP was initiated 109 times by 68 participants (34.0%). In comparison to reported behavior at baseline, reported high-risk sexual activities on average declined over time for both PEP and non-PEP users. There were no serious drug-related adverse events. There were 11 HIV seroconversions, 10 among non-PEP users and 1 that was a PEP failure. The overall seroincidence was 2.9 per 100 person-years (95% CI = 1.4, 5.1). The expected number of new HIV infections and corresponding expected seroincidence based on the risk profile were 11.8 and 3.1, respectively (P > 0.97). The most commonly reported reasons for not initiating PEP among seroconverters were sex with a steady partner and not considering the exposure to be of sufficiently high risk to warrant PEP. Conclusion: PEP was safe and did not appear to be associated with increases in reported high-risk behavior in our cohort. Ready access to PEP did not appear to substantially affect HIV transmission, suggesting a limited public health impact of this intervention.
引用
收藏
页码:519 / 525
页数:7
相关论文
共 23 条
[1]  
[Anonymous], 1998, MMWR Recomm Rep, V47, P1
[2]  
[Anonymous], 1998, MMWR-MORBID MORTAL W, V47, P1
[3]   Prophylaxis with a nevirapine-containing triple regimen after exposure to HIV-1 [J].
Benn, PD ;
Mercey, DE ;
Brink, N ;
Scott, G ;
Williams, IG .
LANCET, 2001, 357 (9257) :687-688
[4]   A case-control study of HIV seroconversion in health care workers after percutaneous exposure [J].
Cardo, DM ;
Culver, DH ;
Ciesielski, CA ;
Srivastava, PU ;
Marcus, R ;
Abiteboul, D ;
Heptonstall, J ;
Ippolito, G ;
Lot, F ;
McKibben, P ;
Bell, DM .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (21) :1485-1490
[5]   REDUCTION OF MATERNAL-INFANT TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 WITH ZIDOVUDINE TREATMENT [J].
CONNOR, EM ;
SPERLING, RS ;
GELBER, R ;
KISELEV, P ;
SCOTT, G ;
OSULLIVAN, MJ ;
VANDYKE, R ;
BEY, M ;
SHEARER, W ;
JACOBSON, RL ;
JIMENEZ, E ;
ONEILL, E ;
BAZIN, B ;
DELFRAISSY, JF ;
CULNANE, M ;
COOMBS, R ;
ELKINS, M ;
MOYE, J ;
STRATTON, P ;
BALSLEY, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (18) :1173-1180
[6]   Human immunodeficiency virus type 1 drug resistance testing: a comparison of three sequence-based methods [J].
Erali, M ;
Page, S ;
Reimer, LG ;
Hillyard, DR .
JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (06) :2157-2165
[7]   Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVMET 012 randomised trial [J].
Guay, LA ;
Musoke, P ;
Fleming, T ;
Bagenda, D ;
Allen, M ;
Nakabiito, C ;
Sherman, J ;
Bakaki, P ;
Ducar, C ;
Deseyve, M ;
Emel, L ;
Mirochnick, M ;
Fowler, MG ;
Mofenson, L ;
Miotti, P ;
Dransfield, K ;
Bray, D ;
Mmiro, F ;
Jackson, JB .
LANCET, 1999, 354 (9181) :795-802
[8]  
HAMERS FF, 2001, 8 C RETR OPP INF FEB
[9]  
Harrison LH, 1999, J ACQ IMMUN DEF SYND, V21, P408
[10]   Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: The San Francisco PEP study [J].
Kahn, JO ;
Martin, JN ;
Roland, ME ;
Bamberger, JD ;
Chesney, M ;
Chambers, D ;
Franses, K ;
Coates, TJ ;
Hatz, MH .
JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (05) :707-714